Core Insights - Edwards Lifesciences exceeded Wall Street expectations for third-quarter results, primarily due to robust demand for its artificial heart valves and other medical devices [1] Financial Performance - The company reported strong sales growth, contributing to a rise in share prices by approximately 3% following the announcement [1]